IMV-M / ImmuVia - LARVOL DELTA

Cytotoxic activity and safety characterization of IMV-M™, a MUC16 × DR5 bispecific antibody. (PubMed, Antib Ther) - "A comparative analysis of three bispecific antibodies, IMV-M (sofituzumab × DR5), 11D10 × DR5, and fluor × DR5, sharing an identical IgG1-anti-DR5 scFv architecture, was performed. IMV-M showed no significant cytotoxicity toward hepatic cell lines, even in the presence of Fc-directed polyclonal antibodies or clinically relevant concentrations of soluble CA125. These findings suggest that IMV-M cytotoxic activity requires clustering on MUC16, that CA125 at clinically relevant concentrations does not mediate IMV-M neutralization, and that aggregate formation with secondary antibodies or soluble MUC16 does not induce off-target toxicity."

Journal • Oncology

Tumor-selective regression through MUC16-guided DR5 (TNFRSF10B) clustering by the bispecific anti-MUC16×anti-DR5 antibody IMV-M™ (AACR 2026) - "IMV-M also lacked cytotoxicity toward hepatic cell lines.MethodsThree bispecific antibodies sharing identical anti-DR5 arms were generated: Sofituzumab (h5A3)×Lexatumumab scFv, 11D10/DR5×Lexatumumab scFv, and (anti-fluorescein)×Lexatumumab scFv. These findings indicate a low risk of off-target hepatic toxicity, consistent with the benign safety profile of earlier anti-DR5 antibodies.ConclusionsEffective DR5 agonism by bispecific antibodies requires high-order receptor clustering. IMV-M achieves this through MUC16-mediated assembly of multiple antibody molecules on a single MUC16 molecule, enabling potent, tumor-selective apoptosis without hepatotoxicity."

Bispecific • Oncology • MUC16 • TNFRSF10B